SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Edwards Lifesciences Corporation (EW) trades at a trailing P/E of 43.6, forward P/E of 26.3. Trailing earnings yield is 2.30%, forward earnings yield 3.80%. PEG 0.42 (Peter Lynch undervalued ≤1.0). Graham Number is $27.18.
Criteria proven by this page:
- VALUE (32/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 43.6).
- Forward P/E 26.3 (down from trailing 43.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.42 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 2.30% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.80% as earnings recover.
- Analyst consensus target $96.38 (+23.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 74/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
32/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EW
Valuation Multiples
P/E (TTM)43.6
Forward P/E26.3
PEG Ratio0.42
Forward PEG0.42
P/B Ratio4.51
P/S Ratio7.69
EV/EBITDA31.9
Per Share Data
EPS (TTM)$1.84
Forward EPS (Est.)$2.97
Book Value / Share$17.81
Revenue / Share$10.45
FCF / Share$2.30
Yields & Fair Value
Earnings Yield2.30%
Forward Earnings Yield3.80%
Dividend Yield0.00%
Graham Number$27.18
SharesGrow IV$108.39 (+38.6%)
Analyst Target$96.38 (+23.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
35.0 |
2.25 |
7.62 |
6.73 |
- |
| 2017 |
38.2 |
3.78 |
7.94 |
6.92 |
- |
| 2018 |
44.4 |
2.56 |
10.20 |
8.61 |
- |
| 2019 |
46.4 |
1.01 |
11.71 |
11.18 |
- |
| 2020 |
69.0 |
-3.22 |
12.42 |
12.95 |
- |
| 2021 |
53.7 |
0.65 |
13.84 |
15.43 |
- |
| 2022 |
30.3 |
14.63 |
7.95 |
8.58 |
- |
| 2023 |
33.0 |
-5.41 |
6.96 |
9.23 |
- |
| 2024 |
10.6 |
0.05 |
4.43 |
8.13 |
- |
| 2025 |
46.4 |
-0.63 |
4.82 |
8.22 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.87 |
$2.96B |
$569.5M |
19.2% |
| 2017 |
$0.96 |
$3.44B |
$622.1M |
18.1% |
| 2018 |
$1.13 |
$3.72B |
$722.2M |
19.4% |
| 2019 |
$1.64 |
$4.35B |
$1.05B |
24.1% |
| 2020 |
$1.30 |
$4.39B |
$823.4M |
18.8% |
| 2021 |
$2.38 |
$5.23B |
$1.5B |
28.7% |
| 2022 |
$2.44 |
$5.38B |
$1.52B |
28.3% |
| 2023 |
$2.30 |
$6B |
$1.4B |
23.4% |
| 2024 |
$6.97 |
$5.44B |
$4.17B |
76.7% |
| 2025 |
$1.83 |
$6.07B |
$1.07B |
17.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.97 |
$2.83 – $3.02 |
$6.68B |
$6.63B – $6.72B |
16 |
| 2027 |
$3.32 |
$3.17 – $3.42 |
$7.34B |
$7.27B – $7.41B |
16 |
| 2028 |
$3.73 |
$3.54 – $3.92 |
$8.07B |
$8.06B – $8.07B |
4 |
| 2029 |
$4.20 |
$4.13 – $4.27 |
$8.89B |
$8.76B – $9B |
2 |
| 2030 |
$4.56 |
$4.48 – $4.64 |
$9.68B |
$9.55B – $9.81B |
2 |
